Download PDF
Thromb Haemost 2002; 87(05): 824-830
DOI: 10.1055/s-0037-1613091
Review Article
Schattauer GmbH

Pharmacokinetics of Recombinant Factor IX after Intravenous and Subcutaneous Administration in Dogs and Cynomolgus Monkeys

K. McCarthy
1   Wyeth Research, Cambridge MA
,
P. Stewart
2   University of North Carolina at Chapel Hill, School of Medicine Department of Pathology and Laboratory Medicine, NC, USA
,
J. Sigman
2   University of North Carolina at Chapel Hill, School of Medicine Department of Pathology and Laboratory Medicine, NC, USA
,
M. Read
2   University of North Carolina at Chapel Hill, School of Medicine Department of Pathology and Laboratory Medicine, NC, USA
,
J. C. Keith Jr.
1   Wyeth Research, Cambridge MA
,
K. M. Brinkhous
2   University of North Carolina at Chapel Hill, School of Medicine Department of Pathology and Laboratory Medicine, NC, USA
,
T. C. Nichols
2   University of North Carolina at Chapel Hill, School of Medicine Department of Pathology and Laboratory Medicine, NC, USA
,
R. G. Schaub
1   Wyeth Research, Cambridge MA
› Author Affiliations
Further Information

Publication History

Received 08 September 2001

Accepted after revision 28 January 2002

Publication Date:
11 December 2017 (online)

Also available at
    Permissions and Reprints

Summary

Hemophilia B therapy requires intravenous (IV) infusions of large volumes of factor IX due to the low concentration of factor IX in concentrates (∼100 IU/mL). High concentration recombinant factor IX (rFIX) could be a significant advance since it would reduce the large volumes necessary for IV dosing and allow for low-volume subcutaneous (SC) administration. To evaluate high concentration factor IX, we produced formulations with either 2,000 or 4,000 IU/mL and studied the SC bioavailability in beagle dogs, cynomolgus monkeys and hemophilia B dogs along with efficacy in hemophilia B dogs. Beagle dog SC bioavailability was 86.4% using a 2000 IU/mL formulation and 77.0% using a 4000 IU/mL formulation. Monkey bioavailability of a 4000 IU/mL formulation of rFIX was 34.8%. A single SC administration of 200 IU/kg (4000 IU/mL) of rFIX to hemophilia B dogs, produced factor IX clotting activity above 5% for 5 days with a bioavailability of 48.6%. High concentration SC rFIX has an acceptable pharmacokinetic profile in monkeys and dogs, and produces a sustained FIX activity in hemophilic dogs.

Keywords

Factor IX - hemophilia B - subcutaneous - dogs - cynomolgus monkeys
 

  • References

  • 1 Hedner U, Davie EW. Factor IX. In: Hemostasis and Thrombosis: Basic Principles and Clinical Practice. J. B. Lippincott Company; Philadelphia, PA: 1982: 29-38.
    Google Scholar
  • 2 Brinkhous KM, Sigman J, Read MS, Stewart PF, McCarthy KP, Timony GA, Leppanen SD, Rup BJ, Keith JC, Garzone PD, Schaub RG. Recombinant Human Factor IX: Replacement Therapy, Prophylaxis, and Pharmacokinetics in Canine Hemophilia B. Blood 1996; 88: 2603-10.
    PubMedGoogle Scholar
  • 3 Brinkhous K, Landen C, Monroe D, Liles D, Read M, Roberts IX HF. Pathophysiology and Gene Therapy of Canine Hemophilia: Dynamics of F. IX Distribution from Extravascular Sites (Subcutaneous, Intramuscular, and Intraperitoneal). FASEB J 07 1993; A117.
    PubMedGoogle Scholar
  • 4 Liles D, Landen CN, Monroe DM, Lindley CM, Read MS, Roberts HR, Brinkhous KM. Extravascular Administration of Factor IX: Potential for replacement Therapy of Canine and Human Hemophilia B. Thromb Haemost 1997; 77 (05) 944-8.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 5 Harrsion S, Adamson S, Bonam D, Brodeur S, Charlebois T, Clancy B, Costigan R, Drapeau D, Hamilton M, Hanley K, Kelley B, Knight A, Leonard M, McCarthy M, Oakes P, Sterl K, Switzer M, Walsh R, Foster W. The manufacturing process for recombinant factor IX. Seminars in Hematology 1998; 35 (2, Suppl 2): 4-10.
    PubMedGoogle Scholar
  • 6 Keith Jr JC, Ferranti TJ, Misra B, Frederick T, Rup B, McCarthy K, Faulkner R, Bush L, Schaub RG. Evaluation of Recombinant Human Factor IX: Pharmacokinetic Studies in the Rat and the Dog. Thromb Haemost 1995; 73 (01) 101-5.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 7 Barrow EM, Bullock WR, Graham JB. A study of the carried state for plasma thromboplastin component (PTC, Christmas factor) deficiency, utilizing a new assay procedure. J Lab Clin Med 1959; 55: 745.
    PubMedGoogle Scholar
  • 8 Rowland M, Tozer TN. Clinical Pharmacokinetics Concepts and Applications. 3rd edition. Williams & Wilkins Media, PA; 1995: 38.
    Google Scholar
  • 9 McCarthy KP, Timony GA, DeCoste ML, Keutzer TA, Rup BJ, Leppanen S, Frederick T, Garzone PD. Pharmacokinetics of Recombinant Human Factor IX in Beagel Dogs. Thromb Haemost 1995; 73: 1016.
    PubMedGoogle Scholar
  • 10 Russell DE, Stewart PF, Elwell DR, Nichols TC, Bellinger DA, Brinkhous KM, Rup BJ, Keith JC, Leitermann K, McCarthy KP, Schaub RG, Read MS. Subcutaneous neonatal administration of recombinant factor IX (BeneFix™) induces immune tolerance in hemophilia B dogs. Blood. 1997 90. Suppl 2662.
    PubMedGoogle Scholar
  • 11 Russell DE, Nichols TC, Elwell DR, Bellinger DA, Rup BJ, Keith JC, Leitermann K, McCarthy KP, Schaub RG, Read MS. Maintenance of immune tolerance in hemophilia B dogs by subcutaneous administration of recombinant human factor IX (BeneFix). Blood. 1998 92. Suppl 1.
    PubMedGoogle Scholar
  • 12 Nilsson IM. Is haemophilia prophylaxis achievable in the context of self-sufficiency?. Blood Coagul Fibrinolysis 1995; 05 (04) S71-S75.
    PubMedGoogle Scholar
  • 13 Liesner RJ, Khair K, Hann IM. The impact of prophylactic treatment on children with severe haemophilia. Br J Haematol 1996; 92: 973-8.
    CrossrefPubMedGoogle Scholar
  • 14 Löfqvist T, Nilsson IM, Berntorp E, Pettersson H. Haemophilia prophylaxis in young patients – a long-term follow-up. J Int Med 1997; 241: 395-400.
    CrossrefPubMedGoogle Scholar
  • 15 Manco-Johnson MJ, Nuss R, Geraghty S, Funk S, Kilcoyne R. Results of Secondary Prophylaxis in Children with Severe Hemophilia. Am J Hematol 1994; 47: 113-7.
    CrossrefPubMedGoogle Scholar